NCT06176690 Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
| NCT ID | NCT06176690 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Baylor College of Medicine |
| Condition | CD30-Positive Diffuse Large B-Cell Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-10-27 |
| Primary Completion | 2028-07-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 90 participants in total. It began in 2025-10-27 with a primary completion date of 2028-07-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibodies and T cells to treat cancer. Antibodies bind to foreign substances, and T cells are infection-fighting white blood cells that can kill tumor cells. Both approaches have shown promise but have not been sufficient to cure most patients. In prior studies, an antibody targeting CD30, a protein found on some T cells and cancer cells, was joined to T cells through gene transfer to create CD30.CAR T cells. Another study showed encouraging responses using CD30.CAR T cells made from a patient's own blood and returned to the same patient (autologous cells). In an ongoing study, patients have been treated with CD30.CAR T cells derived from healthy donors (allogeneic cells), allowing use of banked cells without individualized manufacturing. This approach has shown promising clinical activity with no safety concerns to date. In this study, investigators are evaluating CD30.CAR-EBVST cells modified with an additional molecule called C7R, which has been shown in laboratory studies to enhance anti-cancer effects. The study aims to assess the safety and effectiveness of these allogeneic, banked C7R-modified CD30.CAR-EBVST cells and determine whether they may help treat lymphoma. As an added safety measure, the modified T cells include a marker called iC9. If significant side effects occur, patients may receive rimiducid, which can eliminate the infused T cells. Rimiducid is not yet FDA approved but has been tested in patients without significant side effects.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis and clinical course falling into one of the following categories: 1. Hodgkin lymphoma 2. CD30+ aggressive B-cell lymphoma 3. ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma 4. ALK-positive anaplastic T cell lymphoma 2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory. 3. Age 12 to 75. 4. Bilirubin less than or equal to 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin less than or equal to 3 times the upper limit of normal). 5. AST less than 3 times the upper limit of normal. 6. Estimated GFR \> 70 mL/min. 7. Pulse oximetry of \> 90% on room air 8. Karnofsky or Lansky score of \> 60%. 9. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy. 10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom. 11. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form. Exclusion Criteria: 1. Received an investigational cell therapy or vaccine within the past 6 weeks. 2. Received an investigational small molecule drug within the past 2 weeks. 3. Received anti-CD30 antibody-based therapy within the previous 4 weeks. 4. History of hypersensitivity reactions to murine protein-containing products. 5. Pregnant or lactating. 6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion). 7. Current use of systemic corticosteroids at a dose equivalent to or higher than 10 mg/day of prednisone. 8. Active significant, uncontrolled bacterial, viral or fungal infection. 9. Symptomatic cardiac disease (NYHA Class III or IV disease).
Contact & Investigator
Premal Lulla, MD
PRINCIPAL INVESTIGATOR
Baylor College of Medicine
Frequently Asked Questions
Who can join the NCT06176690 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 75 Years, studying CD30-Positive Diffuse Large B-Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06176690 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06176690 currently recruiting?
Yes, NCT06176690 is actively recruiting participants. Contact the research team at lulla@bcm.edu for enrollment information.
Where is the NCT06176690 trial being conducted?
This trial is being conducted at Houston, United States, Houston, United States.
Who is sponsoring the NCT06176690 clinical trial?
NCT06176690 is sponsored by Baylor College of Medicine. The principal investigator is Premal Lulla, MD at Baylor College of Medicine. The trial plans to enroll 90 participants.